Aims:  

Cancer Immuno Perspectives (CIP) stands as an international journal that provides state-of-the-art, authoritative review articles at the intersection of cancer immunology and immunotherapy. Our core mission is to provide clinicians and researchers with the most up-to-date knowledge in cancer immune research and therapeutic advancements. CIP is dedicated to curating a collection of high-impact manuscripts that demonstrate the synergy of integrating oncology research with other fields, fostering novel diagnostic methods and therapeutic strategies for human cancers. We seek contributions that are not only at the forefront of their respective fields but also offer fresh insights and methodologies to the cancer-immune community.

Scope:

Our journal has a particular interest in topics such as endogenous anti-tumor immunity, the role of inflammation in tumor promotion, the significance of cancer antigens, and the development of vaccines and antibodies. We also focus on cellular therapy, cytokines, immune regulation, immune suppression, and the immunomodulatory effects of cancer treatment. To broaden and deepen our scope, we are expanding our focus to include the following rapidly growing and innovative fields in cancer immunology and immunotherapy. The scope of CIP encompasses a wide range of topics, including but not limited to:

50. Endogenous Anti-Tumor Immunity: We examine the innate and adaptive immune responses that spontaneously counteract neoplastic growth, revealing the underlying mechanisms of tumor regression and resistance to cancer.
50. Inflammation and Tumor Promotion: Our focus is on the intricate relationship between inflammation and cancer development, illuminating how chronic inflammation fosters oncogenic transformation and drives tumorigenesis.
50. Cancer Antigens: We lead the discovery and detailed characterization of tumor-specific antigens, essential for developing precise immunotherapies that enable the immune system to identify and eliminate cancer cells.
50. Vaccines and Antibodies: We are committed to advancing the development and application of cancer vaccines and monoclonal antibodies, with an emphasis on strategies that enhance antigen presentation, boost immune recognition, and precisely target tumors.
50. Cellular Therapy: We utilize T cells and NK cells in adoptive immunotherapies, exploring the potential of chimeric antigen receptor (CAR) modifications and genetic engineering to boost the effectiveness of cell-based cancer treatments.
50. Cytokines: We analyze the diverse roles of cytokines in shaping the cancer immunity landscape, from their ability to strengthen immune responses to their complex influence on tumor development.
50. Immune Regulation: We chart the balance between immune activation and suppression in cancer, concentrating on the molecular interactions that dictate immune response outcomes and therapeutic opportunities.
50. Immune Suppression: We scrutinize the strategies by which tumors evade immune detection, including the exploitation of immune checkpoints and the alteration of immune cell function, assessing the impact on immunotherapeutic approaches.
50. Immunomodulatory Effects of Cancer Treatment: We assess the profound effects of conventional cancer therapies on the immune system, exploring potential synergies with immunotherapies and the potential for abscopal effects.
50. Cancer Immunotherapy Combinations: We explore the potential of combining different immunotherapies to enhance antitumor immunity, surpassing the effects of single-agent treatments.
50. Oncolytic Virus Therapy: We investigate the development and application of oncolytic viruses, designed to precisely target and destroy cancer cells while stimulating the immune system's quiescent responses. Our goal is to understand the full range of their mechanisms and therapeutic potential in the battle against cancer.

By covering these areas, CIP aims to offer a comprehensive platform for disseminating the latest research and advancements in cancer immunology and immunotherapy, fostering the exchange of knowledge and the development of novel therapeutic strategies.